Department of Haematology, St George's Hospital, Blackshaw Road, London SW17 0QT, UK.
Hematol Oncol Clin North Am. 2009 Dec;23(6):1275-97. doi: 10.1016/j.hoc.2009.08.009.
Persistent thrombocytopenia may be the consequence of chronic infections with hepatitis C virus (HCV), human immunodeficiency virus (HIV), and Helicobacter pylori, and should be considered in the differential diagnosis of primary immune thrombocytopenia (ITP). Studies have shown that on diagnosis of infections, treatment of the primary disease often results in substantial improvement or complete recovery of the thrombocytopenia. In patients with thrombocytopenia due to HCV-related chronic liver disease, the use of eltrombopag, a thrombopoietin receptor agonist, normalizes platelet levels, thereby permitting the initiation of antiviral therapy. Antiviral therapy with highly active antiretroviral therapy for HIV has aided in platelet recovery, with a corresponding decrease in circulating viral load. Thrombocytopenia in the absence of other disease symptoms requires screening for H. pylori, especially in countries such as Japan, where there is a high prevalence of the disease and the chances of a platelet response to eradication therapy are high.
持续性血小板减少症可能是丙型肝炎病毒 (HCV)、人类免疫缺陷病毒 (HIV) 和幽门螺杆菌慢性感染的后果,在原发性免疫性血小板减少症 (ITP) 的鉴别诊断中应考虑到这一点。研究表明,在诊断感染后,对原发性疾病的治疗通常会导致血小板减少症的显著改善或完全恢复。在因 HCV 相关慢性肝病导致血小板减少症的患者中,使用血小板生成素受体激动剂艾曲波帕可使血小板水平正常化,从而允许开始抗病毒治疗。针对 HIV 的高效抗逆转录病毒疗法的抗病毒治疗有助于血小板恢复,同时循环病毒载量相应下降。在没有其他疾病症状的情况下出现的血小板减少症需要筛查幽门螺杆菌,特别是在日本等该病患病率较高且血小板对根除治疗有反应机会较高的国家。